22 lines
6.6 KiB
JSON
22 lines
6.6 KiB
JSON
{
|
|
"2026-03-24": {
|
|
"company_of_interest": "LMT",
|
|
"trade_date": "2026-03-24",
|
|
"market_report": "LMT entered a clear distribution phase after peaking at $692 on Mar 2. By Mar 23, price fell to $616.25, -11% from the high. Key signals: broke below 50 SMA ($624.81) for first time in the observation period; RSI 40.12 declining (approaching but not at oversold); MACD 1.35 near zero-line crossover (imminent); MACD histogram -7.01 (most negative, deepening); price closed below Bollinger lower band ($619.85); Mar 20 saw 6.51M shares (institutional distribution). Long-term trend intact: 200 SMA $483, price 27.6% above it. ATR $17.35. Key support $610-616, then $600 psychological. Short-term BEARISH, long-term BULLISH.",
|
|
"sentiment_report": "Overall Net Sentiment 5.9/10 Moderately Bullish. Institutional: 6.5/10. Retail: 5.5/10. Contract/revenue: 7.5/10. AI/tech narrative: 7/10. Momentum/technical: 4/10 bearish. Legal: 4.5/10 negative. Geopolitical: 5/10 highly uncertain (Iran talks vs $200B budget). $200B Pentagon budget underappreciated in retail. $627 50DMA reclaim would rapidly shift sentiment. Social debate: 'is $616 a gift or a trap?'",
|
|
"news_report": "BULLISH: Pentagon seeks $200B supplemental for Iran conflict (directly benefits F-35, PAC-3, HIMARS, precision munitions); $23B Gulf arms sale includes LMT missiles; Greece $36B Achilles Shield (38 F-16 Viper upgrades + counter-drone via Fortem Technologies); neuromorphic AI partnership with BrainChip; IBD names LMT clear sector outperformer; ITA defense ETF +52.34% YTD. BEARISH: Trump 5-day Iran strike pause + diplomatic talks; U.S.-Ukraine peace talks underway; Chinese claim U.S. has 2 months rare earth reserves; $4.25B federal IP lawsuit (Napoli Shkolnik vs LMT); RTX wins $11.74B missile contract; consecutive -1.58% and -1.78% daily declines; GD outperforming LMT on diplomatic news.",
|
|
"fundamentals_report": "Market cap $142.6B. Forward P/E 19.28x (attractive), TTM P/E 28.65x (distorted by Q2 anomaly). Forward EPS $31.97 vs TTM $21.51 (+49% recovery expected). FY2025 FCF ~$6.9B (4.8% yield). Revenue TTM $75B. Q2 2025 gross margin anomaly: 4% (vs normal 11-13%) — cause unknown, likely one-time fixed-price contract charge. Net debt improving $20.3B (Q2) → $17.6B (Q4). Operating margin 9.01% below peers (RTX/NOC 10-12%). Negative tangible book -$8.9B. Deferred revenue $11.44B (strong backlog signal). Dividend 2.19% at 45% FCF payout (safe). Share count declining 237M → 231.9M. Beta 0.197.",
|
|
"investment_debate_state": {
|
|
"bull_argument": "Defense supercycle with $200B Pentagon budget + $23B Gulf sale + $36B Greece Achilles Shield = locked-in revenue. Forward P/E 19.28x is attractive with 49% EPS recovery. $6.9B FCF (4.8% yield). Q2 anomaly one-time. Neuromorphic AI (BrainChip) and counter-drone (Fortem) partnerships = next-gen moat. RSI 40 approaching oversold = contrarian entry. 200 SMA $483 intact as long-term support. Staged accumulation is disciplined risk management. 5-day ceasefire does not cancel F-35 orders. Base $700-750, bull $800+.",
|
|
"bear_argument": "Q2 gross margin 4% — cause UNKNOWN, cannot model recovery, forward EPS thesis built on sand. TTM P/E 28.65x on company with negative tangible book -$8.9B, net debt $17.58B, D/E 338x. Q2 FCF negative. Mar 20 volume = institutional distribution, not retail capitulation. RSI at 40 is falling, not bottoming. Below 50 SMA + below Bollinger lower band = technical breakdown. MACD zero-line crossover imminent. Trump Iran pause + Ukraine peace talks unwinding geopolitical risk premium. RTX winning missile contracts in LMT's core territory. $4.25B lawsuit = tail risk. $445 stop = 28% drawdown = reckless. Wait for Q1 2026 margin confirmation."
|
|
},
|
|
"trader_investment_decision": "BUY. Technical setup: RSI approaching oversold, 200 SMA intact as bedrock at $483 (+27.6% above). Fundamental anchor: 49% EPS recovery, $6.9B FCF, $11.44B deferred revenue at 19.28x forward P/E. Staged accumulation respects near-term uncertainty. Risk-reward: $700-750 target vs $500 exit = 2:1 minimum. Diplomatic risks are real discounts, not structural impairments. FINAL TRANSACTION PROPOSAL: BUY.",
|
|
"risk_debate_state": {
|
|
"aggressive_argument": "Strong BUY. $200B budget unpriced. 49% EPS recovery in defense supercycle. RSI approaching oversold = capitulation entry. 200 SMA bedrock at $483. BrainChip AI and counter-drone = next-gen moat. Staged entry is disciplined. Defense procurement is 5-15 year cycle — 5-day ceasefire doesn't cancel F-35 orders. Base $700-750, bull $800+. FCF 4.8% yield is compelling. Beta 0.197 = low systematic risk.",
|
|
"conservative_argument": "WAIT/PASS. Q2 margin cause unknown — cannot model recovery. Balance sheet fragile (338x D/E, -$8.9B tangible book). 28% stop-loss is reckless. Institutional distribution on Mar 20 = smart money selling. Q2 FCF negative. RTX winning core missile contracts. Diplomatic de-escalation undermining premium. $4.25B lawsuit + rare earth supply = asymmetric tail risks. Return after Q1 2026 confirms margin recovery.",
|
|
"neutral_argument": "Initiate SMALL position with tighter stop ($570-580 = 7% vs 28%). Direction is correct but sizing and risk management too aggressive pre-confirmation. Q2 margin mystery is the central unresolved question. Distribution on Mar 20 is institutional, not retail capitulation. $200B budget and $11.44B deferred revenue are real. Balance sheet concerning but not existential. Small initial tranche + Q1 2026 earnings as key fundamental gate for adding size."
|
|
},
|
|
"investment_plan": "BUY (staged accumulation). Phase 1 (40%): Enter now at ~$616; RSI approaching oversold, diplomatic discount priced in. Stop at ~$445. Phase 2 (40%): Add on Q1 2026 earnings confirming gross margin recovery to 11-13%. Phase 3 (20%): Add on 50 SMA reclaim + MACD bullish crossover. Price targets: base $700-750, bull $800+, bear $500 (exit trigger). Core thesis: 49% forward EPS recovery, 19.28x forward P/E, $6.9B FCF, $11.44B deferred backlog, defense supercycle.",
|
|
"final_trade_decision": "OVERWEIGHT. Initiate small starter position (20% of intended allocation) at ~$616. Stop-loss $570-580 (7% downside, not 28%). Add second tranche (40%) on Q1 2026 gross margin recovery above 8%. Add third tranche (40%) on sustained FCF recovery confirmation. Base target $700-750 (12-18 months). Full position only after margin normalization is confirmed in hard data. The $449 stop in the original plan is replaced with the $570-580 level to preserve capital for redeployment at the Q1 2026 confirmation trigger."
|
|
}
|
|
} |